55.74
0.00
(0.00%)
Pre-market: 56.00
+0.26
(0.47%)
May 21, 5:27AM EDT
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 55.21 - 56.78 |
| 52 week | 24.12 - 57.10 |
| Open | 56.09 |
| Vol / Avg. | 300.00/13.47M |
| Mkt cap | 85.02B |
| P/E | 36.98 |
| Div/yield | - |
| EPS | 1.51 |
| Shares | 1.53B |
| Beta | 0.51 |
| Inst. own | 99% |
Events
Jul 22, 2013
Q2 2013 Gilead Sciences Earnings Release
Jun 18, 2013
Wells Fargo Securities Research & Economics 2013 Healthcare Conference
Jun 11, 2013
34th Annual Goldman Sachs Healthcare Conference
May 29, 2013
38th Annual Deutsche Bank Healthcare Conference
May 20, 2013
Gilead Sciences at UBS Global Healthcare Conference -
May 15, 2013
Gilead Science at Bank of America Merrill Lynch 2013 Health Care Conference -
May 8, 2013
Gilead Sciences Annual Stockholders Meeting -
May 2, 2013
First Quarter 2013 Gilead Sciences Earnings Conference Call -
May 2, 2013
Q1 2013 Gilead Sciences Earnings Release
Mar 9, 2013
Gilead Sciences at The American College of Cardiology Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 28.35% | 26.53% |
| Operating margin | 40.50% | 41.33% |
| EBITD margin | - | 44.20% |
| Return on average assets | 13.25% | 13.35% |
| Return on average equity | 29.77% | 32.30% |
| Employees | 5,000 | - |
| Carbon Disclosure Rating | - | 96/100 |
Address
333 Lakeside Drive
FOSTER CITY, CA 94404
United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)
FOSTER CITY, CA 94404
United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Transcripts - SeekingAlpha
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.
Officers and directors
| John C. Martin Ph.D. | Chairman of the Board, Chief Executive Officer | |
| John F. Milligan Ph.D. | President, Chief Operating Officer | |
| Robin L. Washington | Chief Financial Officer, Senior Vice President | |
| Norbert W. Bischofberger Ph.D. | Executive Vice President - Research and Development, Chief Scientific Officer | |
| Gregg H. Alton | Executive Vice President - Corporate and Medical Affairs | |
| Kevin B. Young CBE | Executive Vice President - Commercial Operations | |
| Per Wold-Olsen | Director | |
| John F. Cogan Jr. | Independent Director | |
| Etienne F. Davignon | Independent Director | |
| Carla A. Hills | Independent Director |